We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bioluminescence Sheds Light on Critical Pathway

By Biotechdaily staff writers
Posted on 29 Aug 2005
Researchers have developed an in vivo bioluminescence technique that allowed them to study the kinetics of IKK (IKappa kinase), a critical enzyme in the NF-KappaB pathway, which is a key regulator of cellular activation, proliferation, and apoptosis.

Investigators at the Washington University School of Medicine (St. More...
Louis, MO, USA) genetically engineered a bioluminescent fusion reporter protein that incorporated firefly luciferase into IKB (IKappaB), the protein that comes immediately after IKK in the NF-KappaB pathway. A bioluminescence camera was used to take real-time measurements of the light released by the reporter protein in cell cultures and in living animals.

When the NF-KappaB pathway was enabled, IKK initiated a cascade of reactions that led to the degradation of IKB. In cells containing the IKB reporter protein, the luciferase was broken down. Increased IKK activity was measured as decreased light emitted by the cells.

Results published in the August 2005 issue of Nature Methods demonstrated the validity of the method and showed that it was possible to obtain a continuous, noninvasive readout of the kinetics of ligand-induced IKK activation and the pharmacodynamics of selective inhibitors of this and other proteins in the NF-KappaB pathway.

"Our new system allows researchers to monitor whether drugs for these conditions are hitting this exact molecular target in cell culture and laboratory animals,” said senior author Dr. David Piwnica-Worms, professor of molecular biology, pharmacology, and radiology at Washington University. "In the case of NF-KappaB, there were also methods that monitored IKK activity via changes in the levels of gene activation at the end of the pathway. But those took hours to days to deliver results, and our approach works continuously and in real time.”




Related Links:
Washington University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Immunofluorescence Analyzer
IFA System
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.